Stock Research Monitor: PLX, RDUS, and RIGL
LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. On Monday, the NASDAQ Composite ended the day at 7,630.00, down 1.39%; the Dow Jones Industrial Average edged 0.57% lower, to finish at 25,306.83; and the S&P 500 closed at 2,802.60, marginally slipping 0.58%. Losses were broad based as seven out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Protalix BioTherapeutics Inc. (NYSE AMER: PLX), Radius Health Inc. (NASDAQ: RDUS), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), and Sarepta Therapeutics Inc. (NASDAQ: SRPT). All you have to do is sign up today for this free limited time offer by clicking the link below.
Karmiel, Israel-based Protalix BioTherapeutics Inc.'s stock finished Monday's session 2.96% lower at $0.49 with a total trading volume of 942,635 shares, which was higher than their three months average volume of 570.38 thousand shares. The stock has gained 10.28% in the past month and 18.35% over the past three months. The Company's shares are trading above their 50-day moving average by 7.51%. Moreover, shares of Protalix BioTherapeutics, which focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally, have a Relative Strength Index (RSI) of 56.92. Get the full research report on PLX for free by clicking below at:
Shares in Waltham, Massachusetts headquartered Radius Health Inc. declined 2.30%, ending yesterday's session at $24.18 with a total trading volume of 682,814 shares. The Company's shares are trading below their 50-day moving average by 16.69%. Moreover, shares of Radius Health, which develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology, have an RSI of 28.48. Today's complimentary research report on RDUS is accessible at:
On Monday, South San Francisco, California-based Rigel Pharmaceuticals Inc.'s stock saw a drop of 1.07%, to close the day at $2.78. A total volume of 2.13 million shares was traded. The Company's shares have advanced 19.31% over the last twelve months. The stock is trading below its 50-day moving average by 14.20%. Additionally, shares of Rigel Pharma, which engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases, have an RSI of 40.60. Register now for your free research document on RIGL at:
Shares in Cambridge, Massachusetts headquartered Sarepta Therapeutics Inc. ended the day 3.21% lower at $115.31. A total volume of 1.52 million shares was traded. The stock has gained 51.01% in the previous three months and 182.55% over the last twelve months. The Company's shares are trading above their 200-day moving average by 47.44%. Furthermore, shares of Sarepta Therapeutics, which focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases, have an RSI of 33.61. Click on the link below and see our free report SRPT at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities